Fennec Pharmaceuticals INC Form 4 insider transactions

Christiana Cioffi, Chief Strategy Officer of Fennec Pharmaceuticals, was granted 10,000 restricted share units on March 28, 2025, according to a Form 4 filing.

Director Rosty Raykov reports acquiring and disposing of Fennec Pharmaceuticals shares on March 31, 2025, resulting from the release of restriction from shares awarded on March 31, 2023.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the release of 1,042 common shares from restriction on March 31, 2025, resulting in a decrease in his beneficially owned securities.

Director Rosty Raykov of Fennec Pharmaceuticals sold 10,000 common shares at $6.79 per share on March 5, 2025, according to a Form 4 filing.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the release of 1,042 common shares from restriction on February 28, 2025, resulting in a total beneficial ownership of 131,549 shares.

Director Rosty Raykov reports acquiring and disposing of Fennec Pharmaceuticals common shares on February 28, 2025, resulting from the release of restrictions on previously awarded shares.

Director Chris A. Rallis of Fennec Pharmaceuticals reports exercising options and selling shares to cover tax obligations under a pre-arranged 10b5-1 trading plan.

Director Rosty Raykov of Fennec Pharmaceuticals sold 10,000 common shares on February 5, 2025, at a price of $6.66 per share, according to a Form 4 filing with the SEC.

A Fennec Pharmaceuticals director, Rosty Raykov, acquired 2,431 common shares through the vesting of restricted stock.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, acquired 1,042 common shares through the vesting of restricted stock.

Director Rosty Raykov of Fennec Pharmaceuticals reports the sale of common shares on January 6, 2025, according to a Form 4 filing.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, acquired 1,042 common shares through the vesting of restricted stock.

A Fennec Pharmaceuticals director, Rosty Raykov, acquired 2,431 common shares due to the release of restrictions on previously awarded shares.

Director Rosty Raykov acquired 25,000 common shares of Fennec Pharmaceuticals through option exercise at a price of $2.69 on December 20, 2024.

A Fennec Pharmaceuticals director, Rosty Raykov, sold 796 common shares at $6.04 per share on December 5, 2024, under a pre-arranged 10b5-1 trading plan.

Director Rosty Raykov of Fennec Pharmaceuticals reported acquiring 2,431 shares through the release of restricted stock and selling 1,635 shares under a pre-arranged 10b5-1 plan.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, acquired 1,042 common shares through the vesting of restricted stock.

A Fennec Pharmaceuticals director, Chris A Rallis, exercised options to acquire 10,000 shares and sold 6,409 shares to cover tax obligations.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, exercised stock options to acquire 15,816 common shares at $2.45 per share.

Christiana Cioffi, Chief Strategy Officer of Fennec Pharmaceuticals, was granted 150,000 incentive stock options on November 13, 2024.

Fennec Pharmaceuticals' Chief Commercial Officer, Terry L. Evans, was granted incentive stock options for 150,000 common shares on November 13, 2024.

Fennec Pharmaceuticals' Chief Medical Officer, Pierre Sayad, was granted 150,000 stock options on November 13, 2024, under the company's 2020 Equity Incentive Plan.

Director Rosty Raykov of Fennec Pharmaceuticals reports the sale of 2,431 common shares at $4.31 per share, alongside the release of restrictions on 2,431 previously awarded shares.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition of 1,042 common shares on October 31, 2024.

Director Chris A. Rallis of Fennec Pharmaceuticals exercised stock options and sold a portion of the acquired shares to cover tax obligations, as disclosed in a recent SEC filing.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the release of 1,042 common shares from restriction on September 30, 2024.

Director Rosty Raykov of Fennec Pharmaceuticals reports the sale of 2,431 common shares at $4.94 per share on October 1, 2024, pursuant to a pre-arranged 10b5-1 trading plan.

Director Rosty Raykov of Fennec Pharmaceuticals reports the sale of 2,431 common shares on September 4, 2024, following the release of restricted shares.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition of 1,042 common shares on August 31, 2024.

Director Rosty Raykov amends a previous Form 4 filing to accurately reflect a donation of 26,001 common shares to charity.